Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the appointment of Bradley J. Monk, MD, FACOG, FACS as Lead Cervical Cancer Advisor to the Company. Dr. Monk will be leading the development of Advaxis’ Lm Technology™ platform and assisting with the Company’s multiple clinical programs, including those in HPV-associated cancers (cervical, anal, and head and neck), HER2 expressing tumors and prostate cancer.

“Dr. Monk is highly regarded for his clinical research work in gynecologic oncology. His reputation as an international expert in gynecologic malignancies will be an invaluable asset to the Company as we work with the FDA to complete our special protocol assessment review and planned initiation of our Phase 3 AIM2CERV trial in cervical cancer,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “We are thrilled to formally add Dr. Monk to our team. He will be instrumental in moving Advaxis forward as we continue to advance the clinical development of our three immunotherapy candidates based on our Lm Technology™ platform.”

Dr. Monk brings to Advaxis more than 25 years of experience in medical oncology and clinical research. Notably, he serves as the co-primary investigator of GOG 0265, an ongoing Phase 2 study evaluating Advaxis’ axalimogene filolisbac in patients with persistent or recurrent cervical cancer and remains a key contributor to the development of the AIM2CERV registration program. Dr. David Mauro, who previously served as the Company’s Chief Medical Officer, has moved on to the next opportunity in his career.

Dr. Monk is currently director of the Division of Gynecologic Oncology at St. Joseph’s Hospital and Medical Center. He is also a professor in the Department of Obstetrics and Gynecology at the University of Arizona’s College of Medicine, and at the Creighton University School of Medicine. He is board certified by the American Board of Obstetrics & Gynecology and is a diplomate of the National Board of Medical Examiners. (Original Source)

Shares of Advaxis closed last Friday at $6.82. ADXS has a 1-year high of $30.13 and a 1-year low of $6.28. The stock’s 50-day moving average is $9.03 and its 200-day moving average is $12.59.

On the ratings front, Advaxis has been the subject of a number of recent research reports. In a report issued on December 17, Janney Montgomery Scott analyst Roy Buchanan assigned a Buy rating on ADXS, with a price target of $22, which represents a potential upside of 222.6% from where the stock is currently trading. Separately, on December 15, H.C. Wainwright’s Swayampakula Ramakanth reiterated a Buy rating on the stock and has a price target of $30.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Roy Buchanan and Swayampakula Ramakanth have a total average return of -27.6% and -30.4% respectively. Buchanan has a success rate of 11.1% and is ranked #3384 out of 3622 analysts, while Ramakanth has a success rate of 11.1% and is ranked #3600.

Advaxis Inc is a clinical development stage biotechnology company. The Company is engaged in discovery, development and commercialization of Lm-LLO immunotherapies for cancer and infectious diseases.